CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS.

Giovanna CapodiventoChiara DemichelisMarinella CarpoRoberto FancelluErika SchirinziDaniele SeveriDavide VisigalliDiego Franciotta Fiore ManganelliGabriele SicilianoAlessandro BeronioElisabetta CapelloPaola Lanteri Eduardo Nobile-Orazio Angelo Schenone Luana Benedetti Lucilla Nobbio

Published in: Journal of neurology, neurosurgery, and psychiatry (2020)

CSF SM is a diagnostic and staging wet biomarker for acquired demyelinating neuropathies and may effectively improve the management of patients affected by GBS and CIDP.

Keyphrases

lymph node
cerebrospinal fluid